Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
Consolidated Revenue EUR 70.2 million in Q4 2025, up 6.8% year-on-year. Growth driven by strong performance in Materialise Medical, offset by slight declines in Software and Manufacturing.
Gross Profit Margin EUR 40.8 million in Q4 2025, representing 58.1% of revenue, an increase from the previous year due to higher revenue and operational efficiencies.
Adjusted EBIT EUR 4 million in Q4 2025, a margin of 5.7%, compared to a loss of EUR 1.2 million in Q4 2024. Improvement due to increased gross margin and lower operating expenses.
Net Profit EUR 6.2 million in Q4 2025, more than double the EUR 2.9 million in Q4 2024, driven by higher revenue and operational improvements.
Net Cash Position EUR 70.8 million at the end of Q4 2025, an increase of EUR 10 million compared to the end of 2024, supported by positive free cash flow.
Materialise Medical Revenue EUR 37 million in Q4 2025, up 16% year-on-year. Growth driven by a 23% increase in Medical Devices and Services revenue.
Materialise Software Revenue EUR 11 million in Q4 2025, stable year-on-year. Recurring revenue grew by 4%, while nonrecurring revenue declined by 19%.
Materialise Manufacturing Revenue EUR 22.2 million in Q4 2025, down 2% year-on-year due to macroeconomic headwinds, particularly in prototyping.
Adjusted EBITDA EUR 9.5 million in Q4 2025, more than double the EUR 4.3 million in Q4 2024, with a margin of 13.6%. Improvement driven by higher revenue and cost control.
Deferred Revenue EUR 48.8 million at the end of Q4 2025, an increase of EUR 3.5 million in the quarter, consistent with seasonal patterns.
Mimics Flow: Released a new version with enhanced functionality, a new licensing system, and a new pricing structure. The update includes AI algorithms for high-volume applications, improved 3D planning, and a unified platform for case discussions. The licensing system reduces overhead and introduces subscription pricing models.
CO-AM Solutions: Introduced three tailored CO-AM solutions (Professional, NPI, Enterprise) and CO-AM Brix, a low-code automation technology. These solutions aim to enhance workflow automation, interoperability, and productivity in additive manufacturing.
Dual Listing on Euronext Brussels: Completed a dual listing on Euronext Brussels to complement the NASDAQ listing, providing access to a broader European investor audience and operational flexibility.
Aerospace and Defense Projects: Awarded key projects including the SONRISA project for quality assurance in 3D printed aircraft parts and the Eurodrone project for Environmental Control Systems.
Operational Efficiencies: Automated production processes using CO-AM Brix, significantly reducing nesting time, build processing time, and error rates.
Cost Management: Disciplined cost control and targeted cost reduction measures improved profitability despite macroeconomic challenges.
Platform Consolidation: Merged iMaterialise and Materialise Onsite into a single platform to focus on professional 3D printing markets.
Focus on Key Verticals: Shifted focus towards high-growth industries like aerospace and defense, aligning with strategic goals.
Macroeconomic headwinds in manufacturing: Persistent macroeconomic challenges are negatively impacting demand, particularly in prototyping, leading to a 2% year-on-year revenue decline in Q4 2025 and a 13% decline for the full year.
Foreign exchange effects: Unfavorable foreign exchange rates, primarily from a weaker U.S. dollar, have weighed on the company's top line, impacting revenue growth.
Transition to subscription-based software model: The ongoing shift to a cloud and subscription-based business model in the Software segment has led to a 7% decline in annual revenue for 2025, with nonrecurring revenue dropping by 19% in Q4.
Manufacturing segment profitability: The Manufacturing segment reported a negative adjusted EBITDA of minus EUR 4.2 million for 2025, reflecting challenges in achieving profitability amidst declining revenues.
Regulatory and certification challenges in aerospace: Participation in projects like SONRISA and Eurodrone involves complex quality assurance and certification processes, which could pose operational and financial risks.
Dependence on key verticals: The company's strategic focus on high-growth verticals like aerospace and defense introduces risks related to dependency on a limited number of industries for future growth.
Investment in R&D: Increased R&D investments, while necessary for future growth, could strain financial resources if not matched by corresponding revenue growth.
Economic uncertainties in industrial markets: The company anticipates continued macroeconomic headwinds in industrial market segments throughout 2026, which could further impact the Manufacturing segment's performance.
Materialise Medical Segment Growth: The Materialise Medical segment is expected to continue growing at a double-digit pace in 2026.
Materialise Software Segment Transition: The Materialise Software segment will complete its transition to a cloud-based subscription business model in 2026 and will continue investments in a broader AM software ecosystem.
Materialise Manufacturing Segment Outlook: The Materialise Manufacturing segment will intensify its shift towards series manufacturing and dedicated focus sectors, but macroeconomic headwinds in the industrial market segment are expected to persist throughout 2026.
Revenue Guidance for 2026: Revenue for 2026 is expected to be in the range of EUR 273 million to EUR 283 million.
Adjusted EBIT Guidance for 2026: Adjusted EBIT for fiscal year 2026 is expected to reach EUR 10 million to EUR 12 million.
Strategic M&A Opportunities: The company will actively pursue strategic M&A opportunities, leveraging its strong financial position with EUR 134 million in cash and cash equivalents, an improved net cash position, and consistently positive operating and free cash flow.
Share Buyback Program: Materialise announced a share buyback program of up to EUR 30 million. This program started on January 26, 2026. To date, the company has acquired a total of 187,500 shares for a total amount just below USD 1 million.
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
The earnings call reveals a mixed performance with a 4% revenue increase but a significant drop in EBIT and net profit, indicating financial struggles. The guidance remains flat, and management's vague responses in the Q&A add uncertainty. Competitive pressures, regulatory issues, and economic factors pose risks. Despite positive cash flow and R&D investments, the negative trends in manufacturing and software revenues, coupled with unclear future projections, suggest a negative sentiment. The lack of market cap data prevents a more precise prediction, but the overall sentiment leans negative.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.